雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Genomic Diagnosis of Bile Duct Cancer Taito FUKUSHIMA 1 , Makoto UENO 1 1Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Kanagawa, Japan Keyword: genomic diagnosis , genomic medicine , FGFR2 pp.1067-1071
Published Date 2022/6/25
DOI https://doi.org/10.24479/endo.0000000228
  • Abstract
  • Look Inside
  • Reference

 The curative treatment for biliary tract cancer (BTC) is surgical resection, but many cases are diagnosed at an advanced stage and are diagnosed as unresectable. Although gemcitabine plus cisplatin, gemcitabine plus S-1, or gemcitabine plus cisplatin plus S-1 are recommended as first-line chemotherapy for unresectable BTC, the prognosis with each treatment is poor. However, the emergence of targeted therapies is rapidly changing the treatment paradigm for BTC. Pemigatinib was approved for BTC patients with FGFR2 fusions/rearrangements in March 2021 based on the high response rate in Japan. In addition, recent studies revealed that microsatellite instability high or high tumor mutation burden, regardless of their primary site, has a promising response to immune checkpoint inhibitors, leading to the approval of pembrolizumab. Accordingly, although tumor biopsy is often difficult for BTC, treatment strategies based on genetic analysis are important options.


© tokyo-igakusha.co.jp. All right reserved.

基本情報

電子版ISSN 印刷版ISSN 0915-3217 東京医学社

関連文献

もっと見る

文献を共有